Novo Nordisk A/S or Bausch Health Companies Inc.: Who Invests More in Innovation?

Novo Nordisk vs. Bausch Health: R&D Investment Showdown

__timestampBausch Health Companies Inc.Novo Nordisk A/S
Wednesday, January 1, 201424600000013762000000
Thursday, January 1, 201558280000013608000000
Friday, January 1, 201645500000014563000000
Sunday, January 1, 201736600000014014000000
Monday, January 1, 201841400000014805000000
Tuesday, January 1, 201947100000014220000000
Wednesday, January 1, 202045200000015462000000
Friday, January 1, 202146500000017772000000
Saturday, January 1, 202252900000024047000000
Sunday, January 1, 202360400000032443000000
Monday, January 1, 202448062000000
Loading chart...

In pursuit of knowledge

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key to staying ahead. Novo Nordisk A/S and Bausch Health Companies Inc. are two giants in this arena, but their investment strategies in research and development (R&D) tell different stories.

Novo Nordisk A/S: A Leader in R&D

From 2014 to 2023, Novo Nordisk A/S consistently outpaced Bausch Health in R&D spending. By 2023, Novo Nordisk's investment in innovation surged to over 32 billion, marking a staggering 135% increase from 2014. This commitment underscores their focus on pioneering treatments and maintaining a competitive edge.

Bausch Health: Steady but Modest

In contrast, Bausch Health's R&D expenses grew by approximately 145% over the same period, reaching 604 million in 2023. While their growth rate is impressive, the absolute figures highlight a more conservative approach compared to Novo Nordisk.

This data reveals not just numbers, but strategic priorities that shape the future of healthcare innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025